CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.47B, above the global median of $1.2B
- FinancialsAltman Z-Score 3.75: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.45%Above 5Y avg (3.75%)
Annual Rate
CNY 1.43Paid annual
Payout Ratio
75.7%Moderate
Payback Period
23.0 yr
Last Ex-Dividend
Jun 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
23.29BCNY3.47B · vs all stocks (USD)
Trailing P/E
14.10xRevenue (TTM)
10.75BCNY1.60B · vs all stocks (USD)
Profit Margin
15.58%Beta
0.1140xvs all stocks
52-Week Change
-32.27%vs all stocks
Market Capitalization
23.29BCNY3.47B · vs all stocks (USD)
Enterprise Value
19.67BCNY2.93B · vs all stocks (USD)
Trailing P/E
14.10xForward P/E
10.45xPrice to Sales (TTM)
2.17xPrice to Book (MRQ)
1.74xEnterprise to Revenue
1.83xEnterprise to EBITDA
6.99xGross Margin
55.08%Profit Margin
15.58%Operating Margin
18.52%Return on Assets (TTM)
5.93%Return on Equity (TTM)
13.42%Revenue (TTM)
10.75BCNY1.60B · vs all stocks (USD)
Revenue per Share (TTM)
12.09CNYUpdated Sep 18, 2026Quarterly Revenue Growth
-31.10%Gross Profit (TTM)
6.82BCNY1.02B · vs all stocks (USD)
EBITDA (TTM)
2.70BCNY403.34M · vs all stocks (USD)
Net Income (TTM)
1.67BCNY249.75M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-44.90%Operating Cash Flow (TTM)
3.22BCNY480.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.11BCNY314.36M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.43CNYUpdated Sep 18, 2026Trailing Annual Dividend Yield
5.45%vs all stocks
5-Year Average Dividend Yield
3.75%vs all stocks
Payout Ratio
75.66%Minority Interest (Equity)
1.66BCNYFY2025 · Dec 31, 2025Revenue
12.02BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.10BCNYFY2025 · Dec 31, 2025Gross Profit
7.92BCNYFY2025 · Dec 31, 2025Operating Income
2.77BCNY413.91M · vs all stocks (USD)
Pre-tax Income
2.86BCNYFY2025 · Dec 31, 2025Income Tax Expense
451.01MCNYFY2025 · Dec 31, 2025Net Income
2.41BCNYFY2025 · Dec 31, 2025EBIT
2.92BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.59BCNYFY2025 · Dec 31, 2025Research & Development
937.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
3.30BCNYFY2025 · Dec 31, 2025Other Operating Expenses
171.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
297.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
57.21MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.27CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.27CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
891.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
891.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.41BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-387.79MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.59BCNYFY2025 · Dec 31, 2025Free Cash Flow
2.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
7.44BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.41BCNYFY2025 · Dec 31, 2025Other Non-cash Items
126.16MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-279.10MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
327.50MCNYFY2025 · Dec 31, 2025Capital Expenditures
-572.15MCNYFY2025 · Dec 31, 2025Purchase of Investments
-8.93BCNYFY2025 · Dec 31, 2025Sale of Investments
7.60BCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.86BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.76BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.91BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-4.84BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.03BCNYFY2025 · Dec 31, 2025Other Financing Charges
-595.09MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.56BCNYFY2025 · Dec 31, 2025Shares Outstanding
887.91MSharesUpdated Sep 18, 2026Float Shares
460.63MSharesUpdated Sep 18, 2026% Held by Insiders
45.41%vs all stocks
% Held by Institutions
5.91%vs all stocks
Total Cash (MRQ)
8.31BCNY1.24B · vs all stocks (USD)
Total Cash per Share (MRQ)
9.35CNYUpdated Sep 18, 2026Total Debt (MRQ)
3.46BCNY515.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2368xCurrent Ratio (MRQ)
1.55xBook Value per Share (MRQ)
15.05CNYUpdated Sep 18, 2026Total Assets
23.99BCNY3.58B · vs all stocks (USD)
Total Current Assets
16.12BCNYFY2025 · Dec 31, 2025Total Liabilities
8.44BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.87BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.22BCNYFY2025 · Dec 31, 2025Total Current Liabilities
7.22BCNYFY2025 · Dec 31, 2025Cash
9.19BCNYFY2025 · Dec 31, 2025Cash Equivalents
114.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
9.31BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.34BCNYFY2025 · Dec 31, 2025Accounts Receivable
2.25BCNYFY2025 · Dec 31, 2025Inventory
1.56BCNYFY2025 · Dec 31, 2025Accounts Payable
1.32BCNYFY2025 · Dec 31, 2025Short-term Debt
2.29BCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.80MCNYFY2025 · Dec 31, 2025Long-term Debt
766.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
887.91MCNYFY2025 · Dec 31, 2025Retained Earnings
12.74BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
15.55BCNY2.32B · vs all stocks (USD)
52-Week Low
25.74CNYUpdated Sep 18, 202652-Week High
39.95CNYUpdated Sep 18, 202652-Week Change
-32.27%vs all stocks
Beta
0.1140xvs all stocks
50-Day MA
29.25CNYUpdated Sep 18, 2026200-Day MA
32.47CNYUpdated Sep 18, 2026Avg 10-Day Volume
5.15MSharesUpdated Sep 18, 2026Avg 30-Day Volume
7.19MSharesUpdated Sep 18, 2026Diluted EPS (TTM)
1.86CNYUpdated Sep 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.75: safe zoneNotable
Altman Z-Score: 3.75
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.47B, above the global median of $1.2BNotable
Market cap (USD): 3,473,907,327.97Global Median: 1,201,862,193
Revenue is $1.6B, above the global median of $558.46MNotable
Revenue (USD): 1,603,187,603.128Global Median: 558,459,881.051
Levered free cash flow is $314.36M, above the global median of $18.92MNotable
Levered free cash flow (USD): 314,358,752.379Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jinghua Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Xuchang Ketop Testing Research Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Fujian Expressway Development Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities